A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 25, 2014

Primary Completion Date

September 16, 2014

Study Completion Date

December 8, 2014

Conditions

Worsening Chronic Heart FailureDiabetic Nephropathy

Interventions

DRUG

Finerenone (BAY94-8862)

Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.

Trial Locations (1)

Kiel